It may seem we talk a lot about Alzheimer's on here. Unfortunately, it's a topic that affects and reaches into more lives and families than seems fair. So, whenever there is a glimmer of hope, we want to share it with you. With the recent publication of some studies, a new wave of hopeful possibilities is developing.
Lithium, most widely known for its use in treating bipolar disorder, is now emerging as a potential key to understanding and possibly treating Alzheimer's disease. Recent research conducted by institutions such as Harvard Medical School and the National Institutes of Health in 2025 has repositioned lithium as a fundamental element in brain health, revealing how its deficiency may contribute to neurodegenerative conditions like Alzheimer's.
Several studies published in 2025, including one in Nature, found significantly reduced lithium levels in the brains of people suffering from Alzheimer's and mild cognitive impairment. Experimental models demonstrated that restoring these lithium levels—particularly using trace or microdoses—could reverse the formation of amyloid plaques and tau tangles, both hallmark features of Alzheimer's pathology.
The Harvard study further established lithium as a naturally occurring trace element vital for neuronal stability and resilience. Mice treated with lithium orotate not only experienced halted neurodegeneration but also recovered lost memory and restored synaptic function.
Lithium helps protect the brain by blocking an enzyme called glycogen synthase kinase-3 beta (GSK-3β). This enzyme is linked to harmful changes in brain cells, like tau tangles and amyloid plaques. By inhibiting GSK-3β, lithium reduces the risk of neuron damage and cell death. It also boosts levels of brain-derived neurotrophic factor (BDNF) and Bcl-2, which are crucial for maintaining healthy brain connections and preventing cell loss.
Beyond that, lithium also acts as an anti-inflammatory and antioxidant agent, reducing oxidative stress and improving mitochondrial function—both of which are crucial for slowing the progression of Alzheimer's.
Earlier trials using high doses of lithium carbonate encountered issues with toxicity, but more recent studies focus on microdosing strategies using 300 micrograms to 50 milligrams daily. These trace doses appear sufficient to activate protective mechanisms while minimizing side effects. Clinical trials have shown stabilization or improvement of cognitive performance in Alzheimer's patients receiving low-dose lithium.
In ongoing studies, low-dose lithium is being tested as a preventive treatment for mild cognitive impairment—a stage preceding Alzheimer's. Early data suggest that consistent lithium supplementation may delay disease onset in at-risk individuals.
While laboratory and early human results are promising, experts caution that more controlled human trials are necessary to confirm lithium's safety and efficacy for Alzheimer's prevention or treatment. The element's delicate balance—too little leading to neurodegeneration, too much causing toxicity—means that any therapy must rely on tightly regulated microdosing.
Nevertheless, lithium's affordability and accessibility make it an appealing candidate for future Alzheimer's therapies, particularly in low-resource healthcare settings.
Lithium's story has come full circle: once valued for mood stabilization, it is now being recognized as a potential gatekeeper of brain health. If ongoing trials confirm current findings, maintaining optimal lithium levels could become a vital part of Alzheimer's prevention and treatment strategies, offering hope for millions facing cognitive decline.
Sources:
https://www.albemarle.com/us/en/news/lithium-101-what-it-and-why-do-we-need-it
https://www.nih.gov/news-events/nih-research-matters/lithium-levels-tied-alzheimers-disease-dementia
